Comparative Pharmacology
Head-to-head clinical analysis: ERYPAR versus ERYTHRO STATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYPAR versus ERYTHRO STATIN.
ERYPAR vs ERYTHRO-STATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erypoietin receptor agonist; stimulates erythropoiesis by binding to erythropoietin receptors on erythroid progenitor cells.
Erythro-statin is a combination of erythromycin, a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and a statin (HMG-CoA reductase inhibitor) that inhibits cholesterol synthesis. Synergistic effects on inflammation and atherosclerosis are hypothesized.
Intravenous: 100 mg every 12 hours for 7 to 14 days.
200 mg intravenously once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 3-5 hours in adults with normal renal function; may be prolonged to >10 hours in severe renal impairment
2.0-3.5 hours in adults with normal renal function. Extended to 5-8 hours in patients with severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion of unchanged drug (~75%) and metabolites; biliary/fecal elimination accounts for ~20%
Approximately 70-80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion. About 20-30% is eliminated unchanged in feces via biliary secretion.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic